Lactoferricin: A lactoferrin-derived peptide with antimicrobial, antiviral, antitumor and immunological properties

Cellular and Molecular Life Sciences

Volumn 62, Issue 22, 2005, Pages 2588-2598

  Gifford, J L ^a   Hunter, H N ^a,b   Vogel, H J ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b YORK UNIVERSITY   (Canada)

Author keywords

Anti inflammatory; Antimicrobial; Antitumor; Antiviral; Lactoferricin; Lactoferrin; Peptide structure; Protein structure

Indexed keywords

LACTOFERRICIN; LACTOFERRICIN B; LACTOFERRICIN C; LACTOFERRICIN H; LACTOFERRICIN M; LACTOFERRIN; LACTOFERRIN DERIVED PEPTIDE; PEPSIN A; PEPTIDE; UNCLASSIFIED DRUG;

ACIDITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; HUMAN; IMMUNOMODULATION; MEDICAL RESEARCH; NONHUMAN; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; STOMACH; STRUCTURE ACTIVITY RELATION;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; HUMANS; LACTOFERRIN; MOLECULAR SEQUENCE DATA;

EID: 28344438950     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-005-5373-z     Document Type: Review

References (81)

1. Caccavo D., Pellegrino N. M., Altamura M., Rigon A., Amati L., Amoroso A. et al. (2002) Antimicrobial and immunoregulatory functions of lactoferrin and its potential therapeutic application. J. Endotoxin Res. 8: 403-417
2. Baker H. M., Anderson B. F., Kidd R. D., Shewry S. C. and Baker E. N. (2000) Lactoferrin three-dimensional structure: a framework for interpreting function. In: Lactoferrin: Structure, Function and Applications, pp. 3-15. Shimazaki, K. Tsuda H., Tomita M., Kunata T. and Perraudin J. P. (eds.) Elsevier Science, New York
3. Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. and Tomita, M. (1992) Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121: 130-136
4. Hunter H. N., Demcoe A. R., Jenssen H., Gutteberg T. J. and Vogel H. J. (2005) Human lactoferricin is partially folded in aqueous solution and is better stabilized in membrane mimetic solvent. Antimicrob. Agents Chemother 49: 3387-3895
5. Hwang P. M., Zhou N., Shan X., Arrowsmith C. H. and Vogel H. J. (1998) Three-dimensional solution structure of lactoferricin B, an antimicrobial peptide derived from bovine lactoferrin. Biochemistry 37: 4288-4298
6. Zhou N., Tieleman D. P. and Vogel H. J. (2004) Molecular dynamics simulations of bovine lactoferricin: turning a helix into a sheet. Biometals 17: 217-223
7. Epand R. M. and Vogel H. J. (1999) Diversity of antimicrobial peptides and their mechanisms of action. Biochim. Biophy. Acta 1462: 11-28
8. Yamauchi K., Tomita, M., Giehl T. J., and Ellison R. T. (1993) Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment. Infect. Immun. 61: 719-728
9. Dionysius D. A. and Milne J. M. (1997) Antibacterial peptides of bovine lactoferrin: purification and characterization. J. Diary Sci. 80: 667-674
10. Shin K., Yamauchi K., Teraguchi S. Hayasawa H., Tomita M., Otsuka Y. et al. (1998) Antibacterial activity of bovine lactoferrin and its peptides against enterohaemorrhagic Escherichia coli O157:H7. Lett. Appl. Microbiol. 26: 407-411
11. Bellamy W., Takase M., Wakabayashi H., Kawase K. and Tomita M. (1992) Antibacterial spectrum of lactoferricin B, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73: 472-479
12. Wakabayashi H., Bellamy W., Takase M. and Tomita M. (1992) Inactivation of Listeria monocytogenes by lactoferricin, a potent antimicrobial peptide derived from cow's milk. J. Food Prot. 55: 238-240
13. Wakabayashi H., Matsumoto H., Hashimoto K., Teraguchi S., Takase M. and Hayasawa H. (1999) N-acylated and D-enantiomer derivatives of a nonamer core peptide of lactoferricin B showing improved antimicrobial activity. Antimicrob. Agents Chemother. 43: 1267-1269
14. Chapple D. S., Mason D. J., Joannou C. L., Odell E. W., Gant V. and Evans R. W. (1998) Structure-function relationship of antibacterial synthetic peptides homologous to a helical surface region on human lactoferrin against Escherichia coli serotype O111. Infect. Immun. 66: 2434-2440
15. Vorland L. H., Ulvatne H., Rekdal Ø. and Svendsen J. S. (1999) Initial binding site of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand. J. Infect. Dis. 31: 467-473
16. Hancock R. E. W. and Chapple D. S. (1999) Antibiotic peptides. Antimicrob. Agents Chemother. 43: 215-220
17. Chapple D. S., Hussain R., Joannou C. L., Hancock R. E. W., Odell E., Evans R. W. et al. (2004) Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob. Agents Chemother. 48: 2190-2198
18. Ulvatne H., Samuelsen Ø., Haukland H. H., Krämer M. and Vorland L. H. (2004) Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol. Lett. 237: 337-384
19. Vogel H. J., Schibli D. J., Jing W., Lohmeier-Vogel E. M., Epand R. F. and Epand R. M. (2002) Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides. Biochem. Cell Biol. 80: 49-63
20. Hoek K. S., Milne J. M., Grieve P. A., Dionysius D. A. and Smith R. (1997) Antibacterial activity of bovine lactoferrin-derived peptides. Antimicrob. Agents Chemother. 41: 54-59
21. Aguilera O., Ostolaza H., Quiros L. M. and Fierro J. F. (1999) Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. FEBS Lett. 462: 273-277
22. Haukland H. H., Ulvatne H. Sandvik K. and Vorland L. H. (2001) The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett. 508: 389-393
23. Prochiantz A. (2000) Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell Biol. 12: 400-406
24. Zhang L., Rozek A. and Hancock R. E. W. (2001) Interaction of cationic antimicrobial peptides with model membranes. J. Biol. Chem. 276: 35714-35722
25. Castle M., Nazarian A., Yi S. S. and Tempst P. (1999) Lethal effects of apidaecin on Escherichia coli involve sequential molecular interactions with diverse targets. J. Biol. Chem. 274: 32555-32564
26. Subbalakshmi C. and Sitaram N. (1998) Mechanism of antimicrobial action of indolicidin. FEMS Microbiol. Lett. 160: 91-96
27. Hunter H. N., Jing W., Schibli D. J., Trinh T., Park I. Y., Kim S. C. et al. (2005) The interactions of antimicrobial peptides derived from lysozyme with model membrane systems. Biochim. Biophys. Acta 1668: 175-189
28. Strøm M. B., Rekdal Ø. and Svendsen J. S. (2002) The effects of charge and lipophilicity on the antibacterial activity of undecapeptides derived from bovine lactoferricin. J. Pept. Sci. 7: 36-43
29. Vorland L. H., Ulvatne H., Andersen J., Haukland H. H., Rekdal Ø., Svendsen J. S. et al. (1998) Lactoferricin of bovine origin is more active than lactoferricins of human, murine and caprine origin. Scand. J. Infect. Dis. 30: 513-517
30. Kang J. H., Lee M. K., Kim K. L. and Hahm K. (1996) Structure-biological activity relationships of 11-residue highly basic peptide segment of bovine lactoferrin. Int. J. Pept. Res. 48: 357-363
31. Strøm M. B., Haug B. E., Rekdal Ø., Skar M. L., Stense W. et al. (2002) Important structural features of 15-residue lactoferrin derivatives and methods for improvement of antimicrobial activity. Biochem. Cell Biol. 80: 65-74
32. Eliassen L. T., Haug B. E., Berge G. and Rekdal Ø. (2003) Enhanced antitumor activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic C-terminal modifications. J. Pept. Sci. 9: 510-517
33. Haug B. E., Skar M. L. and Svendsen J. S. (2001) Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives. J. Pept. Sci. 7: 425-432
34. Schibli D. J., Hwang P. M. and Vogel H. J. (1999) The structure of the antimicrobial active center of lactoferricin B bound to sodium dodecyl sulphate micelles. FEBS Lett. 446: 213-217
35. Nguyen L. T., Schibli D. J. and Vogel H. J. (2005) Structural studies and model membrane interactions of two peptides derived from bovine lactoferricin. J. Pept. Sci. 11: 379-389
36. Strøm M. B., Rekdal Ø., Stensen W. and Svendsen J. S. (2001) Increased antibacterial activity of 15-residue murine lactoferricin derivatives. J. Pept. Res. 57: 127-139
37. Lejon T., Strøm M. B. and Svendsen J. S. (2001) Antibiotic activity of pentadecapeptides modeled from amino acid descriptors. J. Pept. Sci. 7: 74-81
38. Lejon T., Stiberg T., Strøm M. B. and Svendsen J. S. (2004) Prediction of antibiotic activity and synthesis of new pentade-capeptides based on lactoferricins. J. Pept. Sci. 10: 329-335
39. Bellamy W., Yamauchi K., Wakabayashi H., Takase M., Takakura N., Simamura S. et al. (1994) Antifungal properties of lactoferricin B, a peptide derived from the N-terminal region of bovine lactoferrin. Lett. Appl. Microbiol. 18: 230-233
40. Wakabayashi H., Abe S., Teraguchi S., Hayasawa H. and Yamaguchi H. (1998) Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob. Agents Chemother. 42: 1587-1591
41. Lupetti A., Paulusma-Annema A., Welling M. W., Senesi S., van Dissel J. T. and Nibbering P. (2000) Candidacidal activities of human lactoferrin peptides derived from the N-terminus. Antimicrob. Agents. Chemother. 44: 3257-3263
42. Ueta E., Tanida T. and Osaki T. (2001) A novel bovine lactoferrin peptide, FKCRRWQWRM. suppresses Candida cell growth and activates neutrophils. J. Pept. Res. 57: 240-249
43. Kullberg B. J., Netea M. G., Vonk A. G. and van der Meer J. W. (1999) Modulation of neutrophil functions in host defense against disseminated Candida albicans infection in mice. FEMS Immunol. Med. Microbiol. 26: 299-307
44. Tanida T., Rao, F., Hamada T., Ueta E. and Osaki T. (2001) Lactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor. Infect. Immun. 69: 3883-3890
45. Tanaka T., Omata Y., Saito A., Shimazaki K., Yamauchi K., Takase M. et al. (1995) Toxoplasma gondii: parasiticidal effects of bovine lactoferricin against parasites. Exp. Parasitol. 81: 614-617
46. Omata Y., Satake M., Maeda R., Saito A., Shimazaki K., Yamauchi K. et al. (2001) Reduction of the infectivity of Toxoplasma gondii and Eimeria stiedai sporozoite by treatment with bovine lactoferricin. J. Vet. Med. Sci. 63: 187-190
47. Turchany J. M., Aley S.B. and Gillin F. D. (1995) Giardicidal activity of lactoferrin and N-terminal peptides. Infect. Immun. 63: 4550-4552
48. Andersen J. H., Osbakk S. A., Vorland L. H. Traavik T. and Gutteberg T. J. (2001) Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51: 141-149
49. Berkhout B., van Wamel J. L. B., Beljaars L., Meijer D. K. F., Visser S. and Floris R. (2002) Characterization of the anti-HIV effects of native lactoferrin and other milk proteins and protein-derived peptides. Antiviral Res. 55: 341-355
50. McCann K. B., Lee A., Wan J., Roginski H. and Coventry M. J. (2003) The effect of bovine lactoferrin and lactoferricin B on the ability of feline calicivirus (a norovirus surrogate) and poliovirus to infect cell cultures. J. Appl. Microbiol. 95: 1026-1033
51. Siciliano R., Rega B., Marchetti M., Seganti L., Antonini G. and Valenti P. (1999) Bovine lactoferrin peptidic fragments involved in inhibition of herpes simplex virus type 1 infection. Biochem. Biophys. Res. Commun. 264: 19-23
52. Di Biase A. M., Pietrantoni A., Tinari A., Siciliano R., Valenti P., Antonini G. et al. (2003) Heparin-interacting sites of bovine lactoferrin are involved in anti-adenovirus activity. J. Med. Virol. 69: 495-502
53. Andersen J. H., Jenssen H., Sandvik K. and Gutteberg T. J. (2004) Anti-HSV activity of lactoferrin and lactoferricin is dependent on the presence of heparin sulphate at the cell surface. J. Med. Virol. 74: 262-271
54. Jenssen H., Andersen J. H., Uhlin-Hansen L., Gutteberg T. J. and Rekdal Ø. (2004) Anti-HSV activity of lactoferricin analogues is only partly related to their affinity for heparan sulfate. Antiviral Res. 61: 101-109
55. He J. and Furmanski P. (1995) Sequence specificity and transcriptional activation in the binding of lactoferrin to DNA. Nature 373: 721-724
56. 5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328: 145-151
57. Yasin B., Pang M., Turner J. S., Cho Y., Dinh N. N., Waring A. J. et al. (2000) Evaluation of the inactivation of infectious herpes simplex virus of host-defense peptides. Eur. J. Clin. Microbiol. Infect. Dis. 19: 187-194
58. Yoo Y, Watanabe S., Watanabe R., Hata K, Shimazaki K. and Azuma I. (1997) Bovine lactoferrin and lactoferricin, a peptide derived from bovine lactoferrin, inhibit tumor metastasis in mice. Jpn. J. Cancer Res. 88: 184-190
59. Yoo Y. Watanabe R., Koike Y., Mitobe M., Shimazaki K, Watanabe S. et al. (1997) Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: involvement of reactive oxygen species. Biochem. Biophys. Res. Commun. 237: 624-628
60. Eliassen L. T., Berge G., Sveinbjørnsson B., Svendsen J. S., Vorland L. H. and Rekdal Ø. (2002) Evidence for a direct antitumor mechanism of action of bovine lactoferricin. Anticancer Res. 22: 2703-2710
61. Fadok V. A., de Cathelineau A., Daleke D. L., Henson P. M. and Bratton D. L. (2001) Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J. Biol. Chem. 276: 1071-1077
62. Aramaki Y. Takano S., Arima H. and Tsuchiya S. (2000) Induction of apoptosis in WEHI 231 cells by cationic liposomes. Pharm. Res. 17: 515-520
63. Yang N., Strøm M. B., Mekonnen S. M., Svendsen J. S. and Redal Ø. (2004) The effects of shortening lactoferrin derived peptides against tumour cells, bacteria and normal human cells. J. Pept. Sci. 10: 37-46
64. Yang N., Lejon T. and Redal Ø. (2003) Antitumour activity and specificity as a function of substitutions in the lipophilic sector of helical lactoferrin-derived peptide. J. Pept. Sci. 9: 300-311
65. Kreig A. M., Yi A. K., Matson S., Waldschmidt T. J., Bishop G. A., Teasdale R. et al. (1995) CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549
66. Britigan B. E., Lewis T. S., Waldshcmidt M., McCormick M. L. and Krieg A. M. (2001) Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J. Immunol. 167: 2921-2928
67. Beutler B. and Cerami A. (1988) Tumor necrosis, cachexia, shock and inflammation: a common mediator. Annu. Rev. Biochem. 57: 505-518
68. Andrä J., Lohner K., Blondelle S. E., Jerala R., Moriyon I., Koch M. H. J. et al. (2005) Enhancement of endotoxin neutralization by coupling of a C12-alkyl chain to a lactoferricin-derived peptide. Biochem. J. 385: 135-143
69. Mattsby-Baltzer I., Roseanu A., Motas C., Elverfors J., Engberg I. and Hanson L. Å. (1996) Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr. Res. 40: 257-262
70. Samuelsen Ø., Haukland H. H., Ulvatne H. and Vorland L. H. (2004) Anti-complement effects of lactoferrin-derived peptides. FEMS Immunol. Med. Microbiol. 41: 141-148
71. Walport M. J. (2001) Complement. First of two parts. N. Engl. J. Med. 344: 1058-1066
72. Walport M. J. (2001) Complement. Second of two parts. N. Engl. J. Med. 344: 1140-1144
73. Kijlstra A. and Jeurissen S. H. (1982) Modulation of classical C3 convertase of complement by tear lactoferrin. Immunology 47: 263-270
74. van den Berg R. H., Faber-Krol M. C., van Wetering S., Hiemstra P. S. and Daha M. R. (1998) Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood 92: 3898-3903
75. Vorland L. H., Osbakk S. A., Perstølen T., Ulvatne H., Rekdal Ø., Svendsen J. S. et al. (1999) Interference of the antimicrobial peptide lactoferricin B with the action of various antibiotics against Escherichia coli and Staphylococcus aureus. Scand. J. Infect. Dis. 31: 173-177
76. Wakabayahsi H., Teraguchi S. and Tamura Y. (2002) Increased Staphylococcus-killing activity of an antimicrobial peptide, lactoferricin B, with minocylcin and monoacylglycerol. Biosci. Biotechnol. Biochem. 66: 2161-2167
77. Andersen J. H., Jenssen H. and Gutteberg T. J. (2003) Lactoferrin and lactoferricin inhibit Herpes simplex, 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58: 209-215
78. Kuwata H., Yip T., Tomita M. and Hutchens T. W. (1998) Direct evidence of the generation in human stomach of an antimicrobial peptide domain (lactoferricin) from ingested lactoferrin. Biochim. Biophys. Acta 1429: 129-141
79. Britigan B. E., Hayek M. B., Doebbeling B. N. and Fick R. B. (1993) Transferrin and lactoferrin undergo proteolytic cleavage in the Pseudomonas aeruginosa- infected lungs of patients with cystic fibrosis. Infect. Immun. 61: 5049-5055
80. Haversen L. A., Engberg L., Baltzer L., Dolphin G., Hanson L. A. and Mattsby-Baltzer I. (2000) Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infections in mice. Infect. Immun. 68: 5816-5823
81. Isamida T., Tanaka T., Omata Y., Yamauchi K., Shimazaki K. and Saito A. (1998) Protective effect of lactoferricin against Toxoplasma gondii infection in mice. J. Vet. Med. Sci. 60: 241-244